Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2000
03/02/2000WO2000010596A1 Method of increasing bone toughness and stiffness and reducing fractures
03/02/2000WO2000010595A2 Medicaments for manipulating t-cell immune response
03/02/2000WO2000010594A1 The use of glial cell line-derived neurotrophic factor family-related compounds for regulating spermatogenesis and for preparing male contraceptives
03/02/2000WO2000010593A1 USE OF mCRP TO SLOW CELL GROWTH AND TO PROMOTE MATURATION OF CELLS
03/02/2000WO2000010592A2 Medicaments for preventing or reducing scarring
03/02/2000WO2000010591A1 Peptides for inhibition of herpes simplex virus entry
03/02/2000WO2000010590A2 Cancer treatment
03/02/2000WO2000010589A1 Somatostatin analogs
03/02/2000WO2000010583A1 Human histone deacetylase gene hd4
03/02/2000WO2000010580A2 Neural retinal cells and retinal pigment epithelium cells and their use in treatment of retinal disorders
03/02/2000WO2000010578A1 STABLE HYPOXIA INDUCIBLE FACTOR-1 alpha AND METHOD OF USE
03/02/2000WO2000010549A1 Regulation of substrate activity
03/02/2000WO2000010543A2 Medicament containing platinum complex compounds and the use thereof
03/02/2000WO2000010541A1 Stable spray-dried protein formulations
03/02/2000WO2000010507A2 Use of melanin for inhibition of angiogenesis and macular degeneration
03/02/2000WO2000010389A1 BLOCKADE OF GLUCOSE TOXICITY TO THE β CELLS IN THE ISLETS OF LANGERHANS
03/02/2000WO1999066879A3 Systemic immune activation method using nucleic acid-lipid complexes
03/02/2000WO1999066049A3 A novel gene and method of treating a gram negative bacterial infection
03/02/2000WO1999065513A3 Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders
03/02/2000WO1999065511A3 Composition and method for treatment of pseudomonas infection
03/02/2000WO1999065506A3 Cancer therapy with indolicidin or cationic peptides and their polymer conjugates
03/02/2000WO1999065469A3 Processes to generate submicron particles of water-insoluble compounds
03/02/2000WO1999064869A3 Back pain diagnosis and apparatus for use therein
03/02/2000WO1999064409A3 Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
03/02/2000WO1999064063A3 Collagenase application form
03/02/2000WO1999064059A3 Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
03/02/2000WO1999064054A9 Multibinding inhibitors of topoisomerase
03/02/2000WO1999064043A9 Muscarinic receptor antagonists
03/02/2000WO1999063938A9 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
03/02/2000WO1999063937A3 Multivalent macrolide antibiotics
03/02/2000WO1999063090A3 Protease inhibitor peptides
03/02/2000WO1999062494A3 Membrane-permeable inhibitor of dynamin-mediated endocytosis
03/02/2000WO1999061620A3 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
03/02/2000WO1999061614A3 Human socs proteins
03/02/2000WO1999060126A3 Protein z-dependent protease inhibitor
03/02/2000WO1999060124A9 Differentiation-associated sequences and methods of use therefor
03/02/2000WO1999059037A9 Methods of determining protein activity levels using gene expression profiles
03/02/2000WO1999058642A3 Secreted proteins and polynucleotides encoding them
03/02/2000WO1999058558A3 Cell signaling proteins
03/02/2000WO1999058552A3 Peptides that ellicit t, cellular immunity
03/02/2000WO1999057271A3 Feline cd80, feline cd86, feline cd28, and feline ctla-4 nucleic acid and polypeptides
03/02/2000WO1999057261A3 Human bmp-2 promoter and method for exploring bone-related substance by using the same
03/02/2000WO1999057149A3 Compounds and methods for modulating nonclassical cadherin-mediated functions
03/02/2000WO1999057146A9 Protein mixtures to induce therapeutic angiogenesis
03/02/2000WO1999056767A3 Method for treating cytokine mediated hepatic injury
03/02/2000WO1999055377A9 Polyol-ifn-beta conjugates
03/02/2000WO1999055367A9 INTERNALIZING ErbB2 ANTIBODIES
03/02/2000WO1999054465A3 Gene encoding syntaxin interacting protein
03/02/2000WO1999054449A3 Dyskerine and dyskerine coding dna molecule, vectors containing the same, antibodies against dyskerin and utilization of said elements
03/02/2000WO1999052547A9 Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
03/02/2000WO1999047668A3 Nucleic acid which codes for tumor suppressor proteins, tumor suppressor proteins, a method for the production thereof, an antibody against tumor suppressor proteins, and the use of these substances
03/02/2000WO1999045947A9 In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases
03/02/2000WO1999045108A3 Novel mechanically sensitive mammal potassium channel family activated by polyunsaturated fatty acids and their use particularly for screening medicines
03/02/2000WO1999042596A3 Phosphodiesterase 10
03/02/2000WO1999042088A3 Method for the treatment of diseases or disorders of the inner ear
03/02/2000WO1999036535A9 Apo-2 ligand
03/02/2000WO1999024578A3 Neisserial antigens
03/02/2000DE19941248A1 New cetrorelix analogs containing N-substituted glycine derivatives useful as LHRH antagonists, e.g. for treating hormone-dependent tumors
03/02/2000DE19839337A1 Parenteral medicament for treating antithrombin III deficiency contains potent beta-isoform of antithrombin III
03/02/2000DE19839096A1 A cytokine-inducible gene and related protein useful for modulation of interferon gamma
03/02/2000DE19838097A1 Verfahren zur chromatographischen Reinigung von Insulinen Method for the chromatographic purification of insulins
03/02/2000DE19827457C1 Strukturprotein von AAV, seine Herstellung und Verwendung AAV structural protein, its preparation and use
03/02/2000CA2341903A1 Use of melanin for inhibition of angiogenesis and macular degeneration
03/02/2000CA2341765A1 Trna binding domain
03/02/2000CA2341742A1 Activation and protection of t-cells (cd4+ and cd8+) using an h2 receptor agonist and other t-cell activating agents
03/02/2000CA2341701A1 Medicament containing platinum complex compounds and the use thereof
03/02/2000CA2341586A1 Targeting of molecules to large vessel endothelium using epcr
03/02/2000CA2341558A1 Compositions and methods for protecting organs, tissue and cells from immune system-mediated damage
03/02/2000CA2341516A1 Cationic complexes of polymer-modified adenovirus
03/02/2000CA2341309A1 Use of mcrp for delivery of materials into cells
03/02/2000CA2341017A1 Compounds and methods for enhancing delivery of free polynucleotide
03/02/2000CA2340929A1 Methods to enhance and confine expression of genes
03/02/2000CA2340884A1 49 human secreted proteins
03/02/2000CA2340787A1 An anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
03/02/2000CA2340785A1 Cyclophilin-type peptidyl-prolyl cis/trans isomerase
03/02/2000CA2340692A1 Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
03/02/2000CA2340676A1 Ring modified cyclic peptide analogs
03/02/2000CA2340616A1 Secreted proteins and polynucleotides encoding them
03/02/2000CA2340595A1 Streptavidin mutants having secondary functional domains
03/02/2000CA2340470A1 Leptin-related peptides
03/02/2000CA2340465A1 Genes that regulate hematopoietic blood forming stem cells and uses thereof
03/02/2000CA2340459A1 C-myc is activated by beta-catenin and tcf-4
03/02/2000CA2340457A1 14400 receptor, a g-protein coupled receptor
03/02/2000CA2340456A1 Lats knock-out animal models and their uses
03/02/2000CA2340334A1 14274 receptor, a g-protein coupled receptor related to the edg receptor family
03/02/2000CA2340327A1 Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
03/02/2000CA2340307A1 Artiodactyl epimorphine
03/02/2000CA2340305A1 Hiv suppressor factor derived from scrub typhus
03/02/2000CA2340281A1 Neural retinal cells and retinal pigment epithelium cells and their use in treatment of retinal disorders
03/02/2000CA2340277A1 Human rna-associated proteins
03/02/2000CA2339968A1 Dcr5, a bmp-binding protein, and applications thereof
03/02/2000CA2339871A1 Nucleic acids encoding a functional human purinoreceptor p2x2 and methods of producing and use thereof
03/02/2000CA2339860A1 Human cell signaling proteins (csig)
03/02/2000CA2339800A1 Gene therapy for regulating smooth muscle cell tone
03/02/2000CA2339537A1 Regulation of substrate activity
03/02/2000CA2339036A1 Tpl-2/cot kinase and methods of use
03/02/2000CA2338837A1 Assays, methods and means for modulating nuclear localisation
03/02/2000CA2338644A1 The use of glial cell line-derived neurotrophic factor family-related compounds for regulating spermatogenesis and for preparing male contraceptives
03/02/2000CA2337905A1 Targeted alphavirus and alphaviral vectors
03/01/2000EP0982405A2 Recombinant alphavirus vectors
1 ... 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 ... 3163